CDXC (ChromaDex Corp) שולי רווח גולמי

סמל תאגידי ולוגו של ChromaDex (CDXC)

ChromaDex Corporation leverages trust in Tru Niagen to establish itself as an expert in cellular regeneration. The gross margin on this chart demonstrates the business's adaptability, with the parameter value equal to 61.80. Efficient global supply chains minimize delivery costs for supplements. High profitability is underpinned by an exclusive patent for NR synthesis, which blocks competitors' access to the formula.

CDXC - שולי רווח גולמי chromadex.com בטווח 04.07.2022 - 19.03.2025

פילוחי מדדים מקיפים ואנליטיקה עבור ChromaDex Corp (CDXC)

- מדדי הערכת שווי שוק של העסק:
הערכת שווי פונדמנטלית:CDXC, chromadex.com
פריט של המותג ChromaDex Corp.

Gross margin measures production efficiency by determining the profit share after deducting direct costs of goods sold. By analyzing gross margin profitability, an investor can track operational cost dynamics and the business's ability to maintain pricing power. The metric's high sensitivity to cost of sales confirms the value of the Niagen patents, providing ChromaDex Corporation (CDXC) with premium positioning in the science-based longevity supplement segment.